Endocrinology, Vol 133, 1797-1802, Copyright © 1993 by Endocrine Society

ARTICLES

Bioavailability of insulin-like growth factors (IGFs) in rats determined by the molecular distribution of human IGF-binding protein-3

MS Lewitt, H Saunders and RC Baxter
Department of Endocrinology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

Insulin-like growth factor-binding protein-3 (IGFBP-3) forms a 140- kilodalton (kDa) complex with an acid-labile glycoprotein after complexing with IGF-I or IGF-II. To investigate the bioavailability of circulating IGFs in the rat, we determined the molecular distribution and disappearance of an iv bolus of human IGFBP-3 (130 micrograms/kg). Serum fractions were assayed after size-separation chromatography for human (h) and rat (r) IGFBP-3 with specific RIAs. Within 2 min of injection, 52.9 +/- 1.6% of the hIGFBP-3 appeared in a 140-kDa complex. This form remained in the circulation for hours, whereas hIGFBP-3 in 50- and 30-kDa forms disappeared within 30-60 min. The rapid complexing of hIGFBP-3 to the 140-kDa form did not occur in vitro. Measurement of endogenous rIGFBP-2 indicated that there was minimal exchange of hIGFBP- 3 with rIGFBP-3 in the 140-kDa complex within the 60 min of the in vivo study. To determine the importance of IGF-I in regulating the molecular distribution of hIGFBP-3 in serum, the experiment was repeated in streptozotocin-diabetic rats, with total IGF-I levels 50% lower than control values. In these animals, 40.1 +/- 5.2% of the hIGFBP-3 appeared in the 140-kDa complex 2 min after injection, significantly less than that in controls (P < 0.05), and hIGFBP-3 disappeared more quickly from the circulation than in controls (P < 0.05). After coinjection of recombinant human IGF-I, the retention of hIGFBP-3 in the circulation was prolonged in both control and diabetic animals. Because IGFBP-3 must bind IGF before it can associate with the acid- labile subunit, these findings indicate a much greater availability of IGFs to the circulation than previously estimated.

This article has been cited by other articles:

				R. K. Stoving, J.-W. Chen, D. Glintborg, K. Brixen, A. Flyvbjerg, K. Horder, and J. Frystyk Bioactive Insulin-Like Growth Factor (IGF) I and IGF-Binding Protein-1 in Anorexia Nervosa J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2323 - 2329. [Abstract] [Full Text] [PDF]

				L. D. Payet, S. M. Firth, and R. C. Baxter The Role of the Acid-Labile Subunit in Regulating Insulin-Like Growth Factor Transport across Human Umbilical Vein Endothelial Cell Monolayers J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2382 - 2389. [Abstract] [Full Text] [PDF]

				O.J. Ginther, E.L. Gastal, M.O. Gastal, and M.A. Beg Critical Role of Insulin-Like Growth Factor System in Follicle Selection and Dominance in Mares Biol Reprod, May 1, 2004; 70(5): 1374 - 1379. [Abstract] [Full Text] [PDF]

				C. A. Shoubridge and L. C. Read Preferential Intestinal Delivery of Long[Arg3] Insulin-Like Growth Factor (LR3IGF-I) over IGF-I in Preweaning and Adult Rats Endocrinology, May 1, 2003; 144(5): 1887 - 1893. [Abstract] [Full Text] [PDF]

				J. Frystyk, K. Hojlund, K. N. Rasmussen, S. P. Jorgensen, M. Wildner-Christensen, and H. Orskov Development and Clinical Evaluation of a Novel Immunoassay for the Binary Complex of IGF-I and IGF-Binding Protein-1 in Human Serum J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 260 - 266. [Abstract] [Full Text] [PDF]

				R. C. Baxter, S. Meka, and S. M. Firth Molecular Distribution of IGF Binding Protein-5 in Human Serum J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 271 - 276. [Abstract] [Full Text] [PDF]

				S.-A. Wandji, J. E. Gadsby, F. A. Simmen, J. A. Barber, and J. M. Hammond Porcine Ovarian Cells Express Messenger Ribonucleic Acids for the Acid-Labile Subunit and Insulin-Like Growth Factor Binding Protein-3 during Follicular and Luteal Phases of the Estrous Cycle Endocrinology, July 1, 2000; 141(7): 2638 - 2647. [Abstract] [Full Text] [PDF]

				C. H. Lang, X. Liu, G. J. Nystrom, and R. A. Frost Acute response of IGF-I and IGF binding proteins induced by thermal injury Am J Physiol Endocrinol Metab, June 1, 2000; 278(6): E1087 - E1096. [Abstract] [Full Text] [PDF]

				J. D. Wallace, R. C. Cuneo, R. Baxter, H. Orskov, N. Keay, C. Pentecost, R. Dall, T. Rosen, J. O. Jorgensen, A. Cittadini, et al. Responses of the Growth Hormone (GH) and Insulin-Like Growth Factor Axis to Exercise, GH Administration, and GH Withdrawal in Trained Adult Males: A Potential Test for GH Abuse in Sport J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3591 - 3601. [Abstract] [Full Text] [PDF]

				J. B. M. Janosi, P. A. Ramsland, M. R. Mott, S. M. Firth, R. C. Baxter, and P. J. D. Delhanty The Acid-labile Subunit of the Serum Insulin-like Growth Factor-binding Protein Complexes. STRUCTURAL DETERMINATION BY MOLECULAR MODELING AND ELECTRON MICROSCOPY J. Biol. Chem., August 13, 1999; 274(33): 23328 - 23332. [Abstract] [Full Text] [PDF]

				J. G. Robertson, D. A. Belford, and F. J. Ballard Clearance of IGFs and insulin from wounds: effect of IGF-binding protein interactions Am J Physiol Endocrinol Metab, April 1, 1999; 276(4): E663 - E671. [Abstract] [Full Text] [PDF]

				J. B. M. Janosi, S. M. Firth, J. J. Bond, R. C. Baxter, and P. J. D. Delhanty N-Linked Glycosylation and Sialylation of the Acid-labile Subunit. ROLE IN COMPLEX FORMATION WITH INSULIN-LIKE GROWTH FACTOR (IGF)-BINDING PROTEIN-3 AND THE IGFs J. Biol. Chem., February 26, 1999; 274(9): 5292 - 5298. [Abstract] [Full Text] [PDF]

				J. Frystyk, H. Gronbak, C. Skjarbak, A. Flyvbjerg, H. Orskov, and R. C. Baxter Developmental Changes in Serum Levels of Free and Total Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-1 and -3, and the Acid-Labile Subunit in Rats Endocrinology, October 1, 1998; 139(10): 4286 - 4292. [Abstract] [Full Text] [PDF]

				R. A. Hill and J. M. Pell Regulation of Insulin-Like Growth Factor I (IGF-I) Bioactivity in Vivo: Further Characterization of an IGF-I-Enhancing Antibody Endocrinology, March 1, 1998; 139(3): 1278 - 1287. [Abstract] [Full Text] [PDF]

				S. Rajaram, D. J. Baylink, and S. Mohan Insulin-Like Growth Factor-Binding Proteins in Serum and Other Biological Fluids: Regulation and Functions Endocr. Rev., December 1, 1997; 18(6): 801 - 831. [Abstract] [Full Text]

				K. Higaki, Y. Matsumoto, R. Fujimoto, Y. Kurosaki, and T. Kimura Pharmacokinetics of Recombinant Human Insulin-Like Growth Factor-I in Diabetic Rats    Drug Metab. Dispos., November 1, 1997; 25(11): 1324 - 1327. [Abstract] [Full Text]

				C. Y. Lee, H.-B. Wu, D.-S. Suh, and M. M. Rechler Insulin-Like Growth Factor-I (IGF-I) Concentration in 150-Kilodalton Complexes Containing Human IGF-Binding Protein-3 (hIGFBP-3) after Intravenous Injection of Adult Rats with hIGFBP-3 Endocrinology, April 1, 1997; 138(4): 1649 - 1657. [Abstract] [Full Text] [PDF]

				M. Thoren, A. Hilding, R. C. Baxter, M. Degerblad, I.-L. Wivall-Helleryd, and K. Hall Serum Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-1 and -3, and the Acid-Labile Subunit as Serum Markers of Body Composition during Growth Hormone (GH) Therapy in Adults with GH Deficiency J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 223 - 228. [Abstract] [Full Text] [PDF]